Lunai Bioworks (RENB) has approved a 10:1 reverse stock split of its issued and outstanding common stock, par value $0.0001 per share to be effective 12:01 a.m. ET on September 30. The common stock will trade on Nasdaq under the symbol “LNAI” following the reverse stock split, with a new CUSIP number of 29350E 203. The company expects its common stock to open for trading on a post-split basis on Nasdaq as of the commencement of trading on September 30. The reverse stock split is intended to bring the company into compliance with the minimum bid price requirement for continued listing on Nasdaq. The reverse stock split is expected to reduce the number of shares of the company’s common stock outstanding on or about September 30 from approximately 231,780,434 shares to approximately 23,178,096 shares. The reverse stock split will not affect the number of authorized shares of common stock.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RENB:
- BioSymetrics, Brigham and Women’s Hospital awarded NIH STTR grant
- Lunai Bioworks launches transformer-base platform to secure GenAI
- Lunai Bioworks strengthens European strategy through restructuring
- Renovaro Biosciences Faces Subsidiary Bankruptcy Impact
- Renovaro BioSciences retains American Defense International